UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033159
Receipt number R000037816
Scientific Title Phase2 Clinical Trial of Hepatocyte Growth Factor Gene Therapy for Primary Lymphedema
Date of disclosure of the study information 2018/07/01
Last modified on 2022/06/29 09:31:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase2 Clinical Trial of Hepatocyte Growth Factor Gene Therapy for Primary Lymphedema

Acronym

Phase2 Clinical Trial for Primary Lymphedema

Scientific Title

Phase2 Clinical Trial of Hepatocyte Growth Factor Gene Therapy for Primary Lymphedema

Scientific Title:Acronym

Phase2 Clinical Trial for Primary Lymphedema

Region

Japan


Condition

Condition

Primary Lymphedema

Classification by specialty

Vascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The goal of the present study was to develop the novel gene therapy for lymphedema using hepatocyte growth factor (HGF) plasmid DNA.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Quality of Life (SF-36 and LYMQOL) at 12 and 24 week

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Gene

Interventions/Control_1

Placebo (Saline 3.0ml x8, im)

Interventions/Control_2

Low dose (HGF plasmid DNA 0.05mg/3ml x8, im)

Interventions/Control_3

High dose (HGF plasmid DNA 0.5mg/3ml x8, im)

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1, agree to join the study by a document
2, 20<=age<75
3, age of onset <60
4, edema of one limb, the volume is over 20% compared with another side.
5, diagnosed by lymph scintigraphy
6, treated by physical therapy over 3 months
7, agree to prevent pregnancy

Key exclusion criteria

1, stage 3 by ISL classification
2, aplasia or hyperplasia
3, another hereditary
4, malignancy
5, cellulitis at the time of registration
6, received the operation within 90 days
7, severe disease of liver, kidney, heart, or blood
8, alcohol dependence
9, registration of another clinical trials within 90 days
10, the pregnant
11, received the treatment of another gene therapy
12, unfitness patient

Target sample size

9


Research contact person

Name of lead principal investigator

1st name Yukihiro
Middle name
Last name Saito

Organization

Asahikawa medical university

Division name

Dep. Surgery, Div. Vascular surgery

Zip code

078-8510

Address

2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan

TEL

0166-68-2880

Email

lymph_chiken@asahikawa-med.ac.jp


Public contact

Name of contact person

1st name Yukihiro
Middle name
Last name Saito

Organization

Asahikawa medical university

Division name

Dep. Surgery, Div. Vascular surgery

Zip code

078-8510

Address

2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan

TEL

0166-68-2880

Homepage URL


Email

lymph_chiken@asahikawa-med.ac.jp


Sponsor or person

Institute

Asahikawa medical university

Institute

Department

Personal name



Funding Source

Organization

Asahikawa medical university

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Asahikawa medical university

Address

2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan

Tel

0166-68-2880

Email

lymph_chiken@asahikawa-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 05 Month 21 Day

Date of IRB

2018 Year 05 Month 17 Day

Anticipated trial start date

2018 Year 08 Month 07 Day

Last follow-up date

2019 Year 09 Month 19 Day

Date of closure to data entry

2019 Year 10 Month 30 Day

Date trial data considered complete

2019 Year 11 Month 01 Day

Date analysis concluded

2020 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2018 Year 06 Month 27 Day

Last modified on

2022 Year 06 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037816


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name